Skip to main content

Table 3 Plasma lipid profile and inflammatory mediators before and after simvastatin treatment in patients with CHD and control subjects

From: Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease

 

Controls (n = 186)

CHD group (n = 264)

Before treatment

After treatment

TG (mmol/l)

1.15 ± 0.35

1.58 ± 0.58*

1.14 ± 0.71§

TC (mmol/l)

4.11 ± 0.37

5.14 ± 0.49*

4.35 ± 0.53§

HDL-C (mmol/L)

1.37 ± 0.31

1.10 ± 0.25*

1.29 ± 0.27§

LDL-C (mmol/L)

2.00 ± 0.51

3.1 ± 0.27*

2.32 ± 0.30§

VLDL-C (mmol/L)

0.75 ± 0.21

1.03 ± 0.24*

0.78 ± 0.16§

MMP-9 (ng/ml)

40.78 ± 9.72

78.17 ± 21.43*

60.32 ± 20.30§

TNF-α (pg/ml)

81.23 ± 39.07

136.95 ± 52.41*

102.37 ± 47.19§

IL-10 (pg/ml)

32.18 ± 12.15

98.65 ± 34.79*

50.31 ± 24.28§

  1. Values are expressed as mean ± SD. Comparison between controls and CHD subjects were by unpaired student T-test; comparison between before and after treatment of statin were by paired student T-test. *P <0.0001 compared with control group; § P <0.0001 compared with before treatment. CHD coronary heart disease, MMP9 matrix metalloproteinase 9, IL-10 interleukin-10, TNF-α TNF-alpha, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, VLDL-C very low density lipoprotein cholesterol